Teva: Walking Dead? - Alternative Model

About: Teva Pharmaceutical Industries Limited (TEVA)
by: Ackerman Value Investments
This article is exclusive for subscribers.
Ackerman Value Investments
Long only, value, special situations, growth at reasonable price

This article attempts to provide a clear view of Teva's financials.

This article aims to look at this investment with sufficient margin of safety.

Copaxone stressed by 50% profit segment decline.

This is to assist a very heated discussion in the prior post, "Teva: Walking Dead?”

I am not assuming that Teva (NYSE:TEVA) continues acquiring further companies in the years to come. Assuming this